The Clinical Power of Pilocarpine for Sjögren’s Disease

Your comprehensive guide to Jögren (Pilocarpine 5mg) therapy

about_product

Composition

Pilocarpine Hydrochloride Tablets USP 5 mg

Pilocarpine is a parasympathomimetic drug that activates muscarinic receptors to stimulate natural secretions from salivary, lacrimal, and other exocrine glands.

Mechanism of Action

Pilocarpine is a parasympathomimetic agent that enhances secretion from exocrine glands by activating muscarinic receptors, especially M3 receptors. It increases saliva and tear production while improving mucosal hydration.

receptor

M3 Receptor Activation

Selective muscarinic agonist activity

receptor

Enhances Exocrine Secretion

Stimulates salivary, lacrimal, and mucosal secretions for symptomatic relief

receptor

Improves Mucosal Hydration

Helps restore moisture levels in eyes and mouth through continuous stimulation

Clinical Evidence:

clinical_evidence

Dry Eye Study (Felberg S et al., Arq Bras Oftalmol 2022):

Significant improvement in NEI-VFQ-25 score, TBUT and Schirmer’s test

Salivary Flow Study (Depinoy T et al., Rheumatol Ther 2021):

Significant increase in SSF and USSF (p = 0.018, 0.027)

Dry Eye Pilot Study: Mean Schirmer improvement of 4.37 mm and TBUT of 3.03 seconds (p < 0.001)

clinical_evidence

Guidelines Support

Pilocarpine is recommended by EULAR and BSR as part of symptomatic management in Sjögren's Disease, providing evidence-based support for its clinical use.

Dosage & Administration

Standard Dosing

5 mg four times a day Administer orally with adequate fluids

Titration Strategy

Titrate based on tolerance and response Consider morning-only initiation in sensitive patients

Monitoring

Regular assessment of symptom improvement Monitor for adverse effects

Safety Profile

headache

Common Side Effects

Mild parasympathomimetic effects (sweating, headache)

Gastrointestinal symptoms (nausea, diarrhea)

Usually dose-dependent and transient

Safety Record

No long-term serious AEs reported in trials

Well-established safety profile

Extensive post-marketing experience

References

  1. Felberg S et al., "Efficacy and safety of pilocarpine for treatment of dry eye in patients with Sjögren's Disease." Arq Bras Oftalmol 2022; 85(3):269-276
  2. Depinoy T et al., "Oral pilocarpine for dry mouth in patients with Sjögren's Disease: A systematic review and meta-analysis." Rheumatol Ther 2021; 8(1):219-231
  3. Freige C et al., "Sjögren's Disease: prevalence and healthcare burden in Canada." Canadian Agency for Drugs and Technologies in Health; 2020 Jan 21